scholarly journals Synthesis and Radiation Dosimetry of [<sup>68</sup>Ga]-Ga-Lys<sup>1</sup>, Lys<sup>3</sup>-DOTA-Bombesin (1,14) Antagonist for PET-Imaging, as a Potential Theragnostic Tracer in Oncology

2020 ◽  
Vol 10 (02) ◽  
pp. 29-41
Author(s):  
Juan C. Manrique-Arias ◽  
Quetzali Pitalua-Cortes ◽  
Roberto Pedrero-Piedras ◽  
Géiser Rodríguez-Mena ◽  
Tessy López ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Radiation Dosimetry

Radiation dosimetry estimates of 18 F-alfatide II based on whole-body PET imaging of mice

2015 ◽  
Vol 105 ◽  
pp. 1-5 ◽  
Author(s):  
Si-yang Wang ◽  
Xiao Bao ◽  
Ming-wei Wang ◽  
Yong-ping Zhang ◽  
Ying-jian Zhang ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Radiation Dosimetry ◽  
Whole Body

64Cu-PSMA-BCH: A New Radiotracer for Delayed PET Imaging of Prostate Cancer

2021 ◽  
Author(s):  
Teli Liu ◽  
Chen Liu ◽  
Zhongyi Zhang ◽  
Ning Zhang ◽  
Xiaoyi Guo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Radiation Dosimetry ◽  
Whole Body ◽  
Post Injection ◽  
Human Organ ◽  
Fine Needle ◽  
Fine Needle Aspirates ◽  
Psma Pet

Abstract PurposeDevelop a 64Cu labeled radiopharmaceutical targeting prostate specific membrane antigen (PSMA) and investigate its application for prostate cancer imaging. Methods64Cu-PSMA-BCH was prepared and investigated for stability, PSMA specificity and micro-PET imaging. With the approval of Ethics Committee of Beijing Cancer Hospital (No. 2017KT97), PET/CT imaging in 4 patients with suspected prostate cancer was performed and the radiation dosimetry was estimated. Then, PSMA PET-ultrasound image-guided biopsies were performed on 3 patients and the fine needle aspirates were further performed for autoradiography and immunohistochemistry analysis. Results64Cu-PSMA-BCH was prepared with high radiochemical yield and stability. In vivo study showed higher uptake in PSMA (+) 22Rv1 cells than PSMA (-) PC-3 cells (5.59±0.36 and 1.97±0.22 IA%/106 cells at 1 h). It accumulated in 22Rv1 tumor with increasing radioactivity uptake and T/N ratios from 1 h to 24 h post-injection. In patients with suspected prostate cancer, SUVmax and T/N ratios increased within 24 h post-injection. Compared with image at 1 h post-injection, more tumor lesions were detected at 4 h and 24 h post-injection. The human organ radiation dosimetry showed gallbladder wall was most critical, liver and kidneys were followed, and the whole-body effective dose was 0.0292 mSv/MBq. Two fine needle aspirates obtained by PET-ultrasound guided targeted biopsy showed high radioactive signal by autoradiography, with 100% PSMA expression in cytoplasm and 30% expression in nucleus. Conclusion64Cu-PSMA-BCH was PSMA specific and showed high stability in vivo with lower uptake in liver than 64Cu-PSMA-617. Biodistribution in mice and PCa patients showed similar profile compared with other PSMA ligands and it was safe with moderate effective dosimetry. The increased tumor uptake and T/N ratios by delayed imaging may facilitate the detection of small lesions and guiding targeted biopsies.

Radiation dosimetry of [18F](N-methyl)benperidol as determined by whole-body PET imaging of primates

1997 ◽  
Vol 24 (4) ◽  
pp. 311-318 ◽  
Author(s):  
S.M. Moerlein ◽  
J.S. Perlmutter ◽  
P.D. Cutler ◽  
M.J. Welch
Keyword(s):  
Pet Imaging ◽  
Radiation Dosimetry ◽  
Whole Body

Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer

2016 ◽  
Vol 43 (11) ◽  
pp. 1962-1970 ◽  
Author(s):  
Christian H. Pfob ◽  
Sibylle Ziegler ◽  
Frank Philipp Graner ◽  
Markus Köhner ◽  
Sylvia Schachoff ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Radiation Dosimetry ◽  
Specific Probe

scholarly journals Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients

2019 ◽  
Vol 61 (8) ◽  
pp. 1171-1177 ◽  
Author(s):  
Catherine Meyer ◽  
Magnus Dahlbom ◽  
Thomas Lindner ◽  
Sebastien Vauclin ◽  
Christine Mona ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Pet Imaging ◽  
Radiation Dosimetry

scholarly journals Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studies

2005 ◽  
Vol 32 (8) ◽  
pp. 869-874 ◽  
Author(s):  
Sebastian L. Obrzut ◽  
Andrei O. Koren ◽  
Mark A. Mandelkern ◽  
Arthur L. Brody ◽  
Carl K. Hoh ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Radiation Dosimetry ◽  
Whole Body ◽  
Imaging Studies

scholarly journals Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates

2007 ◽  
Vol 35 (4) ◽  
pp. 771-778 ◽  
Author(s):  
Jo Ann V. Antenor-Dorsey ◽  
Richard Laforest ◽  
Stephen M. Moerlein ◽  
Tom O. Videen ◽  
Joel S. Perlmutter
Keyword(s):  
Pet Imaging ◽  
Radiation Dosimetry ◽  
Whole Body

scholarly journals Whole-body biodistribution and radiation dosimetry of [18F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Wencke Lehnert ◽  
Patrick J. Riss ◽  
Ana Hurtado de Mendoza ◽  
Sandra Lopez ◽  
Gonzalo Fernandez ◽  
...  
Keyword(s):  
Gall Bladder ◽  
Effective Dose ◽  
Cortical Bone ◽  
Pet Imaging ◽  
Movement Disorders ◽  
Radiation Dosimetry ◽  
Bladder Wall ◽  
Whole Body ◽  
Absorbed Doses ◽  
Red Marrow

Abstract Purpose [18F]PR04.MZ is a new PET imaging agent for dopamine transporters, providing excellent image quality and allowing for the evaluation of patients with movement disorders such as Parkinson’s disease. The objective of this study was to evaluate the biodistribution and radiation dosimetry of [18F]PR04.MZ by serial PET imaging. Methods Six healthy subjects (n = 3 males, n = 3 females) were enrolled in this study. A series of 14 whole-body PET/CT scans were acquired until 5.5 h post-injection of 200 ± 11 MBq of [18F]PR04.MZ. After rigid co-registration, volumes of interest were outlined either on CT or PET images. Time-integrated activity coefficients were calculated for selected source organs. Organ absorbed doses, and the effective dose were calculated using IDAC-Dose 2.1. Results Physiological uptake of [18F]PR04.MZ was mainly observed in the striatum, brain, liver, gall bladder, intestine, red marrow and cortical bone. [18F]PR04.MZ was primarily excreted via hepatobiliary clearance and, to a lower extent, via renal clearance. The normalized absorbed doses were highest in gall bladder wall (32.2 ± 6.4 µGy/MBq), urinary bladder wall (27.2 ± 4.5 µGy/MBq), red marrow (26.5 ± 1.4 µGy/MBq), cortical bone surface (26.3 ± 2.5 µGy/MBq), liver (22.5 ± 1.8 µGy/MBq) and kidneys (21.8 ± 1.1 µGy/MBq). The effective dose according to ICRP 60 and 103 was 16.3 ± 1.1 and 16.6 ± 1.5 µSv/MBq, respectively. Conclusion [18F]PR04.MZ has a favourable dosimetry profile, comparable to those of other 18F-labelled PET tracers, and is suitable for larger clinical applications. Trial registration CEC SSM Oriente, Santiago, Chile, permit 20140520.

scholarly journals Comparison of 68Ga-DOTA-Siglec-9 and 18F-Fluorodeoxyribose-Siglec-9: Inflammation Imaging and Radiation Dosimetry

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Helena Virtanen ◽  
Johanna M. U. Silvola ◽  
Anu Autio ◽  
Xiang-Guo Li ◽  
Heidi Liljenbäck ◽  
...  
Keyword(s):  
Sialic Acid ◽  
Pet Imaging ◽  
Radiation Dosimetry ◽  
Lower Cost ◽  
Atherosclerotic Plaques ◽  
Adhesion Protein ◽  
Inflammation Imaging ◽  
Sialic Acid Binding ◽  
Vascular Adhesion ◽  
Vascular Adhesion Protein 1

Sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9) is a ligand of inflammation-inducible vascular adhesion protein-1 (VAP-1). We compared 68Ga-DOTA- and 18F-fluorodeoxyribose- (FDR-) labeled Siglec-9 motif peptides for PET imaging of inflammation. Methods. Firstly, we examined 68Ga-DOTA-Siglec-9 and 18F-FDR-Siglec-9 in rats with skin/muscle inflammation. We then studied 18F-FDR-Siglec-9 for the detection of inflamed atherosclerotic plaques in mice and compared it with previous 68Ga-DOTA-Siglec-9 results. Lastly, we estimated human radiation dosimetry from the rat data. Results. In rats, 68Ga-DOTA-Siglec-9 (SUV, 0.88±0.087) and 18F-FDR-Siglec-9 (SUV, 0.77±0.22) showed comparable (P=0.29) imaging of inflammation. In atherosclerotic mice, 18F-FDR-Siglec-9 detected inflamed plaques with a target-to-background ratio (1.6±0.078) similar to previously tested 68Ga-DOTA-Siglec-9 (P=0.35). Human effective dose estimates for 68Ga-DOTA-Siglec-9 and 18F-FDR-Siglec-9 were 0.024 and 0.022 mSv/MBq, respectively. Conclusion. Both tracers are suitable for PET imaging of inflammation. The easier production and lower cost of 68Ga-DOTA-Siglec-9 present advantages over 18F-FDR-Siglec-9, indicating it as a primary choice for clinical studies.

Sign in / Sign up

Export Citation Format

Share Document